Up­start Akero con­tin­ues its swoosh in­to NASH space with $70M wind­fall round

Akero Ther­a­peu­tics first swooshed on­to the NASH stage with a drug in-li­censed from Am­gen, re­cruit­ing Gilead’s An­drew Cheng as CEO sev­er­al months lat­er and mak­ing a cross-coun­try move to San Fran­cis­co. Now, it’s cap­ping an event­ful year with $70 mil­lion more to bankroll its Phase II work and scale the op­er­a­tions con­sid­er­ably.

Led by Janus Hen­der­son In­vestors, the Se­ries B comes just six months af­ter Akero launched with $65 mil­lion in Se­ries A cash, sug­gest­ing that an IPO could be in sight.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.